ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 957,57
0,54%
Dow Jones
38 675,68
1,18%
DAX
18 001,60
0,54%
Brent Oil
82,765
0,00%
Bitcoin
63 882,30
1,58%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Processa Pharmaceuticals Inc (PCSA)

  7. Processa Pharmaceuticals Inc (PCSA) Actualités

PCSA Processa Pharmaceuticals Inc

2,14
-0,12 (-5,31%)
04 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Processa Pharmaceuticals Inc PCSA NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,12 -5,31% 2,14 06:00:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
2,30 2,15 2,30 2,17 2,26
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
30/4/202414:00GLOBEProcessa Pharmaceuticals Names Dr. Steven Cha Senior Vice..
11/4/202414:00GLOBEProcessa Pharmaceuticals Presents Two Abstracts at the AACR..
28/3/202413:15GLOBEProcessa Pharmaceuticals to Present at the MedInvest Biotech..
25/3/202413:15GLOBEProcessa Pharmaceuticals to Present Data at the American..
21/2/202423:25EDGAR2Form 8-K - Current report
21/2/202414:15GLOBEProcessa Pharmaceuticals to Present at the 2024 BIO CEO &..
14/2/202419:00GLOBEProcessa Pharmaceuticals to Present at The Winter Wrap-Up..
06/2/202414:30EDGAR2Form 8-K - Current report
06/2/202414:30GLOBEProcessa Pharmaceuticals Regains Compliance with Nasdaq..
02/2/202400:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/2/202422:22GLOBEProcessa Pharmaceuticals Announces Closing of $7.0 Million..
31/1/202422:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/1/202416:46EDGAR2Form 8-K - Current report
29/1/202422:15EDGAR2Form 424B4 - Prospectus [Rule 424(b)(4)]
29/1/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
26/1/202415:04GLOBEProcessa Pharmaceuticals Announces Pricing of $7.0 Million..
25/1/202414:35EDGAR2Form 8-K - Current report
25/1/202414:30GLOBEProcessa Pharmaceuticals Announces Successful Completion of..
19/1/202414:00EDGAR2Form 8-K - Current report
19/1/202413:45GLOBEProcessa Pharmaceuticals Announces Expansion of NGC-Cap..
18/1/202414:30EDGAR2Form 8-K - Current report
18/1/202413:45GLOBEProcessa Pharmaceuticals to Effect a 1-for-20 Reverse Stock..
08/1/202422:30EDGAR2Form 8-K - Current report
02/1/202423:06GLOBEProcessa Pharmaceuticals to Present at the Biotech Showcase..
29/12/202314:55EDGAR2Form S-1 - General form for registration of securities under..
19/12/202315:00EDGAR2Form 8-K - Current report
19/12/202315:00GLOBEProcessa Pharmaceuticals Provides Interim Analysis from..
13/12/202315:00GLOBEProcessa Pharmaceuticals Announces Successful Phase 2..
05/12/202323:18EDGAR2Form 8-K - Current report
30/11/202314:15GLOBEProcessa Pharmaceuticals to Present at the MedInvest..
29/11/202314:15GLOBEProcessa Pharmaceuticals Issues Letter to Shareholders..
16/11/202321:10EDGAR2Form 8-K - Current report
15/11/202317:30EDGAR2Form 8-K - Current report
13/11/202322:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/11/202320:45EDGAR2Form 8-K - Current report
13/11/202319:40GLOBEProcessa Pharmaceuticals, Inc. Mourns the Sudden Passing of..
09/11/202314:15GLOBEProcessa Pharmaceuticals to Present at the 20th Orphan Drugs..
01/11/202313:15GLOBEProcessa Pharmaceuticals Announces Formation of Oncology..
16/10/202315:15EDGAR2Form 8-K - Current report
13/10/202319:08GLOBEProcessa Pharmaceuticals to Present at the ThinkEquity..
13/10/202300:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/10/202300:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/10/202300:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/10/202323:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/10/202323:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/10/202323:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/10/202322:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/10/202322:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/10/202316:01EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
05/10/202316:00EDGAR2Form DEF 14A - Other definitive proxy statements

Dernières Valeurs Consultées

NASDAQ
PCSA
Processa Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés